Curiosis큐리오시스

Curiosis is loss-making with revenue of about ₩8.5B over the last twelve months, and its shares have fallen about 30% over three months.

Curiosis, a KOSDAQ-listed maker of life science instruments and lab automation equipment, reported trailing twelve-month revenue of ₩8.5B against an operating loss of ₩7.8B for the period to H1 2026. The company holds ₩17.0B in cash against ₩0.5B in borrowings, and the share price closed at ₩7,950 on 2026-10-22, well below its 52-week high.

What stands out

• Operating margin is about -92.8% on a trailing basis, and 2025 full-year operating margin was about -103.1%, so losses are large relative to sales.
• Free cash flow was about -₩9.0B over the trailing period, and cash of ₩17.0B is the main buffer in the filed figures.
• Book value is valued at about 4.9x and the enterprise value is about ₩104.8B, while P/E is not meaningful because earnings are negative.
• Foreign ownership rose from 3.6% to 6.1% over about 60 days, while foreign and retail net flows over the last 20 days were both slightly negative and institutions were slightly positive.
• Recent filings are mainly insider shareholding reports, an H1 2026 half-year report and investor relations events; no news headlines were in the data.

What to watch

• The next filed results and whether losses narrow relative to the ₩8.5B revenue base.
• Cash burn: trailing free cash flow of about -₩9.0B compared with ₩17.0B in cash.
• Further insider shareholding reports and the pace of any change in foreign ownership.